A clinical genetics approach to stroke in children and young adults — covering monogenic stroke syndromes, CADASIL, mitochondrial stroke-like episodes, hereditary coagulopathies, and the role of genetic testing in guiding diagnosis and secondary prevention.
Tags: Neurogenetics · Advanced
Approximately 5–10% of all strokes and up to 25–30% of strokes in patients under 45 years have a definable genetic cause. Genetic stroke syndromes should be suspected when stroke occurs in young patients, is recurrent, affects multiple family members, is associated with specific non-stroke neurological features, or has characteristic MRI findings. A systematic approach to genetic diagnosis has direct therapeutic implications and informs family member screening.
Key Points
CADASIL is the most common hereditary stroke disorder in adults, caused by autosomal dominant pathogenic variants in NOTCH3 — specifically stereotyped cysteine-altering variants in the epidermal growth factor-like repeat (EGF-r) domain of the extracellular domain, causing protein aggregation in the walls of small arteries throughout the body. It is a primary arteriopathy — not a coagulopathy — affecting cerebral small vessels.
Key Points
Stroke-like episodes (SLEs) in MELAS differ fundamentally from ischemic stroke: they are caused by focal neuronal energy failure, not vascular occlusion. This distinction has critical management implications — thrombolytics are contraindicated. MELAS is most commonly caused by the m.3243A>G variant in MT-TL1 with maternal inheritance and variable heteroplasmy. For comprehensive coverage of MELAS and mitochondrial disorders, see the [[mitochondrial|Mitochondrial Disorders]] module.
Key Points
Several hereditary conditions affecting coagulation or vascular wall structure predispose to ischemic stroke or intracranial hemorrhage. These conditions require specific genetic testing and targeted management distinct from the general approach to stroke secondary prevention.
Key Points
A systematic, stepwise approach to genetic evaluation in young stroke patients maximizes diagnostic yield while remaining cost-effective. The workup is guided by clinical phenotype, stroke mechanism (ischemic vs. hemorrhagic, large vessel vs. small vessel vs. cardioembolic), and family history. Genetic diagnosis has implications for treatment, secondary prevention, and family screening.
Key Points
1. MTHFR C677T homozygosity is found on a thrombophilia panel ordered during young stroke workup. The appropriate clinical response is:
MTHFR C677T is one of the most over-interpreted genetic variants in clinical medicine. The MTHFR variant itself is NOT an independent stroke risk factor. Its clinical relevance is confined to situations where it causes elevated plasma homocysteine. If plasma homocysteine is normal, MTHFR C677T requires no specific intervention. If homocysteine is elevated, folate/B12/B6 supplementation is appropriate to normalize levels. MTHFR testing is not recommended in stroke workup guidelines — measuring homocysteine directly is the correct approach.
2. A 38-year-old woman presents with a third episode of subcortical lacunar stroke. She has a history of migraine with aura since age 28 and her father had dementia and strokes in his 50s. MRI shows extensive periventricular white matter changes and old lacunar infarcts in the external capsule and anterior temporal lobes. The most likely diagnosis is:
CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is suggested by: autosomal dominant family history, recurrent lacunar strokes, migraine with aura as an early symptom, and the characteristic MRI pattern of extensive WMH with prominent anterior temporal lobe and external capsule involvement. NOTCH3 EGF-r domain sequencing is the diagnostic test of choice.
3. A 16-year-old presents with sudden onset cortical blindness. MRI DWI shows restricted diffusion in the bilateral occipital cortex crossing vascular territories. Lactate is 4.2 mmol/L. The acute management should include:
The presentation — adolescent, DWI signal crossing vascular boundaries in the posterior cortex, elevated lactate — is characteristic of a MELAS stroke-like episode (SLE). SLEs are caused by mitochondrial energy failure in neurons, NOT vascular occlusion; thrombolytics are contraindicated and could cause hemorrhage. IV L-arginine (a nitric oxide precursor) is the standard acute treatment for MELAS SLE — it reduces the vascular component of the episode. Anticonvulsants and metabolic support are also given.
4. A 32-year-old man with acroparesthesias, renal insufficiency, and no traditional stroke risk factors presents with a lacunar infarct. His maternal uncle had early renal failure and a stroke at 40. The most appropriate screening test is:
Fabry disease (X-linked GLA deficiency) classically presents in males with acroparesthesias (burning pain in hands/feet), progressive renal disease, and early stroke in the 3rd-4th decade. The maternal family history (X-linked inheritance through maternal uncle) is consistent. Enzyme replacement therapy (agalsidase) is available, making genetic diagnosis directly therapeutic. Alpha-galactosidase A enzyme activity in leukocytes is the first-line test in males; GLA sequencing confirms the variant.
5. A 7-year-old child with sickle cell disease (HbSS) has transcranial Doppler velocities of 220 cm/s in the right MCA. The evidence-based intervention that most reduces stroke risk is:
The STOP trial demonstrated that in children with sickle cell disease and elevated TCD velocities (≥200 cm/s), regular chronic transfusion therapy reducing HbS to <30% reduces first stroke risk by approximately 90% compared to observation. This is the standard of care for high-risk SCD children identified by TCD screening. Hydroxyurea is used for stroke prevention in lower-risk patients or when transfusion is not feasible. Antiplatelet therapy and anticoagulation are not first-line for primary stroke prevention in SCD.